Display options
Share it on

Cytotechnology. 1997 Nov;25(1):35-44. doi: 10.1023/A:1007999313566.

Evaluation of the serum-free medium MDSS2 for the production of poliovirus on vero cells in bioreactors.

Cytotechnology

O W Merten, R Wu, E Couvé, R Crainic

PMID: 22358877 PMCID: PMC3466734 DOI: 10.1023/A:1007999313566

Abstract

The serum-free medium MDSS2 (Merten et al., 1994), was used for cultivating Vero cells as well as for producing poliovirus (Sabin type 1) in static and in perfused micro-carrier cultures. At slightly different growth rates of 0.0120/h and 0.0106/h, respectively, static cultures in serum-containing (SCM) and serum-free (SFM) medium produced titers of (106.75) and 10(6.67) TCID50 per 50 µl; signifying a specific productivity of 0.89 and 1.07 TCID50/c.Serum-free bioreactor cultures of Vero cells on DEAE-dextran microcarriers at 6.25 g/l produced cell densities of about 1.5×10(6)c/ml. After infection with virus (multiplicity of infection (MOI) 0.1-0.3) titers of about 6.3×10(8) TCID50/ml were obtained, signifying an average specific productivity of 7.1 TCID50/c.h. Although these values were 4 and 2 fold, respectively, higher than in classical resum-based production processes (Montagnon et al. Dev. biol. Stand. 1981, 47, 55), a reference culture, for which cell growth was done in SCM and only virus production was done in SFM, produced 2×10(9) TCID/ml with an average specific virus production rate of 18.9 TCID50/c.h. The differences between the fully serum-free and our reference process were mainly due to physiological differences of cells grown in SCM and SFM and also due to strongly modified consumption kinetics after virus infection leading to limitations of one or several essential medium compounds, like glucose and amino acids. Avoiding these limitations by increasing the residual concentration of glucose, glutamine, histidine, and SH-amino acids, led to specific virus production rates (of about 17.9 TCID59/c.h.) comparable to those found in the reference virus production process. The optimisation of the production of the poliovirus (Sabin 1) will be described with respect to the modification of the medium composition.

References

  1. Vaccine. 1993;11(1):82-90 - PubMed
  2. Viral Immunol. 1990 Winter;3(4):243-72 - PubMed
  3. Proc Soc Exp Biol Med. 1962 Oct;111:71-5 - PubMed
  4. Biologicals. 1995 Jun;23(2):185-9 - PubMed
  5. Biotechnol Bioeng. 1992 Feb 5;39(3):327-35 - PubMed
  6. Proc Soc Exp Biol Med. 1961 Aug-Sep;107:834-8 - PubMed
  7. J Gen Virol. 1968 Mar;2(2):243-50 - PubMed
  8. J Virol. 1974 Mar;13(3):557-66 - PubMed
  9. Biotechnol Bioeng. 1985 May;27(5):585-95 - PubMed
  10. Cytotechnology. 1994;14(1):47-59 - PubMed
  11. Dev Biol Stand. 1985;60:349-54 - PubMed
  12. Science. 1949 Jan 28;109(2822):85-7 - PubMed
  13. Dev Biol Stand. 1981;47:55-64 - PubMed
  14. Vaccine. 1995 Sep;13(13):1244-50 - PubMed
  15. Cell Biol Int. 1993 Sep;17(9):885-95 - PubMed
  16. Nature. 1967 Oct 7;216(5110):64-5 - PubMed
  17. Adv Exp Med Biol. 1996;397:141-51 - PubMed
  18. Dev Biol Stand. 1983;55:37-42 - PubMed

Publication Types